Cleveland Clinic and IBM Quantum Breakthrough in Cancer Neoantigen Prediction

A collaboration between the Cleveland Clinic and IBM Quantum has resulted in a significant advancement in cancer neoantigen prediction using quantum computing. The researchers introduced a new framework called Q-CHIPP, which integrates MHC binding and T-cell recognition using Quantum Convolutional Neural Networks (QCNNs). This work establishes a scalable foundation for quantum-enhanced biomedical research.

The team achieved a 6% increase in classification accuracy with fewer training samples compared to classical approaches. They encoded nine-amino-acid peptides into qubits and modeled them using a QCNN architecture initially tested on quantum simulators before transferring optimized methods to actual quantum hardware.

Q-CHIPP's clinical relevance was validated using data from immunotherapy-treated patients with HLA-A*02:01-positive lung cancer, demonstrating its potential to refine neoantigen load predictions. The researchers implemented a hybrid approach to mitigate quantum noise, including Pauli twirling and dynamical decoupling, alongside controlled shot-based sampling.